EP4013880A1 — Rna combinations and compositions with decreased immunostimulatory properties
Assigned to Curevac SE · Expires 2022-06-22 · 4y expired
What this patent protects
The invention relates inter alia to a combination comprising (i) a first component comprising at least one therapeutic RNA and (ii) a second component comprising at least one antagonist of at least one RNA sensing pattern recognition receptor. Further provided are compositions co…
USPTO Abstract
The invention relates inter alia to a combination comprising (i) a first component comprising at least one therapeutic RNA and (ii) a second component comprising at least one antagonist of at least one RNA sensing pattern recognition receptor. Further provided are compositions comprising at least one therapeutic RNA and at least one antagonist of at least one RNA sensing pattern recognition receptor. The combination of the two components is able to reduce immunostimulatory properties of the first component as well as promote expression after administration. Additionally, first and second medical uses, and methods of treating or preventing diseases, disorders or conditions are provided.
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.